Evidence map›Paper›PMID 29419806›Full record

ReviewBrain sciences2018

Neuroprotective Effects of Bioactive Compounds and MAPK Pathway Modulation in "Ischemia"-Stressed PC12 Pheochromocytoma Cells.

Adi Lahiani, Annette Brand-Yavin, Ephraim Yavin, Philip Lazarovici

Abstract readReview
In one paragraph

Review in Brain sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Frontiers in pharmacology · 2025
    Review
  7. Article
  8. Investigating the Pharmacological Mechanisms of Total Flavonoids fromInternational journal of molecular sciences · 2024
    Article
  9. Dexmedetomidine alleviates blood-brain barrier disruption in rats after cerebral ischemia-reperfusion by suppressing JNK and p38 MAPK signaling.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Endogenous FGF21 attenuates blood-brain barrier disruption in penumbra after delayed recanalization in MCAO rats through FGFR1/PI3K/Akt pathway.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. NeuroinflammatoryFrontiers in pharmacology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Adi LahianiSchool of Pharmacy, the Institute for Drug Research, The Hebrew University of Jerusalem, P.O. Box 12065, Jerusalem 9112102, Israel. adi.lahiani@mail.huji.ac.il.
Annette Brand-YavinDepartment of Neurobiology, The Weizmann Institute of Science, Rehovot 7610001, Israel. annette.brand@gmx.net.
Ephraim YavinDepartment of Neurobiology, The Weizmann Institute of Science, Rehovot 7610001, Israel. ephraim.yavin@gmail.com.ORCID 0000-0003-3650-4721
Philip LazaroviciSchool of Pharmacy, the Institute for Drug Research, The Hebrew University of Jerusalem, P.O. Box 12065, Jerusalem 9112102, Israel. philipl@ekmd.huji.ac.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review surveys the efforts taken to investigate in vitro neuroprotective features of synthetic compounds and cell-released growth factors on PC12 clonal cell line temporarily deprived of oxygen and glucose followed by reoxygenation (OGD/R). These cells have been used previously to mimic some of the properties of in vivo brain ischemia-reperfusion-injury (IRI) and have been instrumental in identifying common mechanisms such as calcium overload, redox potential, lipid peroxidation and MAPKs modulation. In addition, they were useful for establishing the role of certain membrane penetrable cocktails of antioxidants as well as potential growth factors which may act in neuroprotection. Pharmacological mechanisms of neuroprotection addressing modulation of the MAPK cascade and increased redox potential by natural products, drugs and growth factors secreted by stem cells, in either undifferentiated or nerve growth factor-differentiated PC12 cells exposed to ischemic conditions are discussed for future prospects in neuroprotection studies.

Indexed as

antioxidantsgrowth factorsischemialipid peroxidationMAP kinasesneuroprotectionNGFoxygen-glucose deprivation and reoxygenation injuryPC12 pheochromocytoma cellsstem cells

Identifiers

PMID29419806
PMCPMC5836051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.